RxDoctor Payments Data

Lisa McDonald, NP

Family · Centreville, MDNPI 1770825747

Payments from drug & device makers

$587in general payments, 2019–2025

Across 20 payments — averaging $29.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$409
  • Novo Nordisk$54
  • GSK$34
  • Pfizer$20
  • Exact Sciences$19
  • Paratek Pharmaceuticals, Inc.$18
  • plus $31 from 2 others

What the payments were for

  • Food & beverage$587100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$587 in reported general payments places this provider in the 60th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$150,120
Medicare patients
318
Services billed
2,234

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide43$45,055
JardianceEmpagliflozin54$44,284
EliquisApixaban51$43,446
XareltoRivaroxaban34$35,621
MounjaroTirzepatide29$28,887
Breztri AerosphereBudesonide/Glycopyr/Formoterol44$28,351
TrulicityDulaglutide27$26,883
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$23,508
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr32$18,005
RybelsusSemaglutide11$13,842
Spiriva HandihalerTiotropium Bromide17$11,592
VascepaIcosapent Ethyl29$9,339
Atorvastatin Calcium476$5,636
Incruse ElliptaUmeclidinium Bromide12$4,178
Omega-3 Acid Ethyl Esters56$3,599

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$54$58,89754 claims
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta$34$45,69082 claims
PfizerEliquis$20$43,44651 claims
AstraZenecaBreztri Aerosphere$409$28,35144 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,843 family providers in Maryland.

Other family in Centreville

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →